HOOK General/Rough Short Position Analysis
Overall:
* Negative EPS
* June 7th conference Asco will most likely lead to a double-top.
* The "surge" is starting to end, if not has already ended. Share price should return to anywhere between $8-11, possibly even lower.
* Medical breakthroughs, as a whole, when it comes to cancers, which this company focuses on, are slow, unlikely, and uncommon. And I suspect, the share price will not be Mooning, anytime soon.
* Negative EPS
* June 7th conference Asco will most likely lead to a double-top.
* The "surge" is starting to end, if not has already ended. Share price should return to anywhere between $8-11, possibly even lower.
* Medical breakthroughs, as a whole, when it comes to cancers, which this company focuses on, are slow, unlikely, and uncommon. And I suspect, the share price will not be Mooning, anytime soon.
免責聲明
這些資訊和出版物並非旨在提供，也不構成TradingView提供或認可的任何形式的財務、投資、交易或其他類型的建議或推薦。請閱讀使用條款以了解更多資訊。